NICE's cost-effectiveness range: Should it be lowered?

PharmacoEconomics

Volumn 32, Issue 7, 2014, Pages 613-615

  Raftery, J P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEALTH CARE COST; HUMAN; MORTALITY; MULTIPLE SCLEROSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; COST BENEFIT ANALYSIS; GOVERNMENT; PRACTICE GUIDELINE; STANDARDS; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; GOVERNMENT AGENCIES; GREAT BRITAIN; GUIDELINES AS TOPIC; HEALTH CARE COSTS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84903993901     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0158-6     Document Type: Editorial

References (22)

1. NICE, Guide to the methods of technological appraisal. Ref: N1618; 2008.
2. NICE, Guide to the methods of technological appraisal. Ref: N0514; 2004.
3. Devlin N, Parkin N. Does NICE have an cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437-52. (Pubitemid 38660393)
4. Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, Mason H, Odejar M, Pinto Prades JL, Robinson A, Ryan M, Shackley P, Smith R, Sugden R, Wildman J; the SVQ Research Team. Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project. HTA J. 2010;14(27). http://www.hta.ac.uk/fullmono/ mon1427.pdf.
5. Martin S, Rice N, Smith PC. The link between health care spending and health outcomes in the new English primary care trusts. York: Centre for Health Economics; 2008.
6. Martin S, Rice N, Smith P. Does health care spending improve health outcomes? J Health Econ. 2008;27:826-42.
7. Martin S, Rice N, Smith P. Comparing costs and outcomes across programmes of health care. Health Econ. 2012;21:316-37.
8. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold final report. University of York CHE; 2013.
9. Barnsley P, Towse A, Karlberg S, Sussex J. Critique of CHE Research Paper 81: methods for the estimation of the NICE cost effectiveness threshold. OHE. Occasional Paper 13/01; 2013.
10. NICE Technology appraisal recommendation summary. http://www.nice.org.uk/ newsroom/nicestatistics/TADecisionsRecommendationSummary.jsp.
11. Raftery J. Costly failure of risk sharing scheme. BMJ. 2010;340:c1672.
12. Latimere C. NICE's end of life decision making scheme: impact on population health. BMJ. 2013;346:f1363. doi:10.1136/bmj.f1363 (Published 21 March 2013).
13. Dakin H, Devlin N, Feng Y, Rice N, O'Neil P, Parkin D. The influence of cost effectiveness and other factors on NICE decisions. OHE Research Paper 13/06; 2013.
14. Apleby J, Poteliakhoff E, Shah K, Devlin N. Using patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitals. J R Soc Med. 2013;106(8):323-31. doi:10.1177/0141076813489678.
15. Dakin H, Gray A, Fitzpatrick R, MacLennan G, Murray D; The KAT Trial Group. Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. http://bmjopen.bmj.com/content/2/1/e000332.full?rss=1.
16. Coronini-Cronberg S, Appleby J, Thompson J. Application of patient-reported outcome measures (PROMs) data to estimate cost-effectiveness of hernia surgery in England. J R Soc Med. 2013;106:323-31.
17. Michaels JA, et al. Randomised clinical trial, observational study and assessment of cost- effectiveness of the treatment of varicose veins (REACTIV Trial). Health Technol Assess. 2006;10(13):1-96.
18. Street A, Gutacker N, Bojke C, Devlin N, Daidone S. Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data. Health Services Deliv Res. 2014;2(1), ISSN 2050-4349. doi:10.3310/hsdr02010.
19. Eckermann S, Pekarsky B. Can the real opportunity cost stand up: displaced services, the straw man outside the room. Pharmacoeconomics 2014;32(4):319-25.
20. Paulden M, McCabe C, Karnon J. Achieving allocative efficiency in healthcare: nice in theory, not so NICE in practice? Pharmacoeconomics 2014;32(4):315-8.
21. Barrett A, Roques T, Small M, Smith R. How much will herceptin really cost? BMJ. 2006;333. doi:10.1136/bmj.39008.624051.BE (Published 23 Nov 2006).
22. Department of Health. Pharmaceutical Price Regulation Scheme 2014; 2013. https://www.gov.uk/government/publications/pharmaceutical-price-regulation- scheme-2014.